share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q：2024财年三季报
美股SEC公告 ·  2024/11/12 13:31

Moomoo AI 已提取核心信息

BeiGene reported robust Q3 2024 financial results, with total revenue reaching $1 billion, a 28.2% increase year-over-year. Product revenue surged 66.9% to $993.4 million, driven by BRUKINSA's global sales of $690.3 million, up 93% YoY. The company reduced its GAAP loss and achieved a second consecutive quarter of positive non-GAAP operating income.Research and development expenses rose 9.5% to $496.2 million, reflecting continued investment in the company's pipeline. Selling, general and administrative expenses increased 24.5% to $455.2 million to support product launches. BeiGene ended the quarter with $2.7 billion in cash and cash equivalents.The company strengthened its leadership in chronic lymphocytic leukemia with BRUKINSA and is advancing pivotal programs for its late-stage hematology pipeline. BeiGene expanded its oncology pipeline with four new molecular entities entering clinical trials this quarter, reaffirming its goal to initiate 10+ by year-end. The company remains focused on its innovative "Fast to Proof of Concept" strategy to rapidly explore clinical potential.
BeiGene reported robust Q3 2024 financial results, with total revenue reaching $1 billion, a 28.2% increase year-over-year. Product revenue surged 66.9% to $993.4 million, driven by BRUKINSA's global sales of $690.3 million, up 93% YoY. The company reduced its GAAP loss and achieved a second consecutive quarter of positive non-GAAP operating income.Research and development expenses rose 9.5% to $496.2 million, reflecting continued investment in the company's pipeline. Selling, general and administrative expenses increased 24.5% to $455.2 million to support product launches. BeiGene ended the quarter with $2.7 billion in cash and cash equivalents.The company strengthened its leadership in chronic lymphocytic leukemia with BRUKINSA and is advancing pivotal programs for its late-stage hematology pipeline. BeiGene expanded its oncology pipeline with four new molecular entities entering clinical trials this quarter, reaffirming its goal to initiate 10+ by year-end. The company remains focused on its innovative "Fast to Proof of Concept" strategy to rapidly explore clinical potential.
百济神州公布了2024年第三季度的强劲财务业绩，总营业收入达到10亿美金，同比增长28.2%。产品营业收入激增66.9%，达到99340万美金，主要得益于BRUKINSA的全球销售额达到69030万美金，同比增长93%。公司减少了GAAP亏损，实现了连续第二个季度的非GAAP营业收入为正。研发支出增长9.5%，达到49620万美金，反映出公司在其研发管线上的持续投资。销售、一般和行政费用增长24.5%，达到45520万美金，以支持产品发布。百济神州在本季度结束时现金及现金等价物达到27亿美金。公司在慢性淋巴细胞白血病领域通过BRUKINSA加强了其领导地位，并在推进晚期肿瘤药物管线的关键项目。百济神州的肿瘤药物管线扩展了四个新的分子实体进入临床试验，重申其目标是在年底前启动10个以上项目。公司继续专注于其创新的“快速概念验证”策略，以快速探索临床潜力。
百济神州公布了2024年第三季度的强劲财务业绩，总营业收入达到10亿美金，同比增长28.2%。产品营业收入激增66.9%，达到99340万美金，主要得益于BRUKINSA的全球销售额达到69030万美金，同比增长93%。公司减少了GAAP亏损，实现了连续第二个季度的非GAAP营业收入为正。研发支出增长9.5%，达到49620万美金，反映出公司在其研发管线上的持续投资。销售、一般和行政费用增长24.5%，达到45520万美金，以支持产品发布。百济神州在本季度结束时现金及现金等价物达到27亿美金。公司在慢性淋巴细胞白血病领域通过BRUKINSA加强了其领导地位，并在推进晚期肿瘤药物管线的关键项目。百济神州的肿瘤药物管线扩展了四个新的分子实体进入临床试验，重申其目标是在年底前启动10个以上项目。公司继续专注于其创新的“快速概念验证”策略，以快速探索临床潜力。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间